Relative atrial natriuretic peptide deficiency and inadequate renin and angiotensin II suppression in obese hypertensive men

Hypertension

Volumn 62, Issue 1, 2013, Pages 147-153

  Asferg, Camilla L ^a   Nielsen, Søren J ^c   Andersen, Ulrik B ^a   Linneberg, Allan ^b,g   Møller, Daniel V ^d   Hedley, Paula L ^d   Christiansen, Michael ^d   Goetze, Jens P ^a,e,g   Esler, Murray ^f   Jeppesen, Jørgen L ^g  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b Research Centre for Prevention and Health   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d STATENS SERUM INSTITUT   (Denmark)

^e Rigshospitalet   (Denmark)

^f BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

aldosterone; angiotensin; hypertension; natriuretic peptides; renin; sympathetic nervous system

Indexed keywords

ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; RENIN; SODIUM;

ADULT; AGED; ANGIOTENSIN BLOOD LEVEL; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CONTROLLED STUDY; HUMAN; HYPERTENSION; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; OBESITY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM EXCRETION; SODIUM INTAKE; URINARY EXCRETION;

ALDOSTERONE; ANGIOTENSIN; HYPERTENSION; NATRIURETIC PEPTIDES; RENIN; SYMPATHETIC NERVOUS SYSTEM;

ADULT; AGED; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; BODY COMPOSITION; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OBESITY; PROGNOSIS; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 84880716941     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.00791     Document Type: Article

References (41)

1. Kurukulasuriya LR, Stas S, Lastra G, Manrique C, Sowers Jr. Hypertension in obesity. Med Clin North Am. 2011;95:903-917.
2. Sarzani R, Salvi F, Dessì-Fulgheri P, Rappelli A. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens. 2008;26:831-843.
3. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, Vasan RS. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109:594-600.
4. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Borch-Johnsen K, Ibsen H, Jørgensen T, Hildebrandt P. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension. 2005;46:660-666.
5. Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, Vasan RS. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation. 2007;115:1345-1353.
6. Khan AM, Cheng S, Magnusson M, Larson MG, Newton-Cheh C, McCabe EL, Coviello AD, Florez JC, Fox CS, Levy D, Robins SJ, Arora P, Bhasin S, Lam CS, Vasan RS, Melander O, Wang TJ. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community- based studies. J Clin Endocrinol Metab. 2011;96:3242-3249.
7. Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension. 2006;48:787-796.
8. Grassi G, Seravalle G, Dell'oro R. Sympathetic activation in obesity: a noninnocent bystander. Hypertension. 2010;56:338-340.
9. Wang TJ. The natriuretic peptides and fat metabolism. N Engl J Med. 2012;367:377-378.
10. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003;42:474-480.
11. Chen J, Gu D, Huang J, Rao DC, Jaquish CE, Hixson JE, Chen CS, Chen J, Lu F, Hu D, Rice T, Kelly TN, Hamm LL, Whelton PK, He J; GenSalt Collaborative Research Group. Metabolic syndrome and salt sensitivity of blood pressure in non-diabetic people in China: a dietary intervention study. Lancet. 2009;373:829-835.
12. Zhao Q, Gu D, Hixson JE, Liu DP, Rao DC, Jaquish CE, Kelly TN, Lu F, Ma J, Mu J, Shimmin LC, Chen J, Mei H, Hamm LL, He J; Genetic Epidemiology Network of Salt Sensitivity Collaborative Research Group. Common variants in epithelial sodium channel genes contribute to salt sensitivity of blood pressure: The GenSalt study. Circ Cardiovasc Genet. 2011;4:375-380.
13. Whelton PK. Urinary sodium and cardiovascular disease risk: informing guidelines for sodium consumption. JAMA. 2011;306:2262-2264.
14. Verdecchia P, Angeli F, Mazzotta G, Gentile G, Reboldi G. Home blood pressure measurements will not replace 24-hour ambulatory blood pressure monitoring. Hypertension. 2009;54:188-195.
15. O'Brien E, Asmar R, Beilin L, et al; European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens. 2003;21:821-848.
16. Yandle TG, Richards AM, Nicholls MG, Cuneo R, Espiner EA, Livesey JH. Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. Life Sci. 1986;38:1827-1833.
17. Usinger L, Ibsen H, Linneberg A, Azizi M, Flambard B, Jensen LT. Human in vivo study of the renin-angiotensin-aldosterone system and the sympathetic activity after 8 weeks daily intake of fermented milk. Clin Physiol Funct Imaging. 2010;30:162-168.
18. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098.
19. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14:540-545.
20. Hansen TW, Kikuya M, Thijs L, Li Y, Boggia J, Björklund- Bodegârd K, Torp-Pedersen C, Jeppesen J, Ibsen H, Staessen JA. Diagnostic thresholds for ambulatory blood pressure moving lower: a review based on a meta-analysis-clinical implications. J Clin Hypertens (Greenwich). 2008;10:377-381.
21. Espiner EA, Richards AM. Atrial natriuretic peptide. An important factor in sodium and blood pressure regulation. Lancet. 1989;1:707-710.
22. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321-328.
23. Newton-Cheh C, Larson MG, Vasan RS, et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet. 2009;41:348-353.
24. International Consortium for Blood Pressure Genome-Wide Association Studies, Ehret GB, Munroe PB, Rice KM, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478:103-109.
25. Johnson T, Gaunt TR, Newhouse SJ, et al. Blood pressure loci identified with a gene-centric array. Am J Hum Genet 2011;89:688-700.
26. Jeppesen JL, Nielsen SJ, Torp-Pedersen C, Hansen TW, Olsen MH, Berg ND, Linneberg A, Madsbad S, Fenger M. Genetic variation in the natriuretic peptide system, circulating natriuretic peptide levels, and blood pressure: an ambulatory blood pressure study. Am J Hypertens. 2012;25:1095-1100.
27. Shenker Y, Sider RS, Ostafin EA, Grekin RJ. Plasma levels of immunoreactive atrial natriuretic factor in healthy subjects and in patients with edema. J Clin Invest. 1985;76:1684-1687.
28. Clinkingbeard C, Sessions C, Shenker Y. The physiological role of atrial natriuretic hormone in the regulation of aldosterone and salt and water metabolism. J Clin Endocrinol Metab. 1990;70:582-589.
29. Ferrari P, Weidmann P, Ferrier C, Dietler R, Hollmann R, Piso RJ, Wey J, Shaw S. Dysregulation of atrial natriuretic factor in hypertension-prone man. J Clin Endocrinol Metab. 1990;71:944-951.
30. Bruun NE, Dige-Pedersen H, Skøtt P. Normal responses of atrial natriuretic factor and renal tubular function to sodium loading in hypertensionprone humans. Blood Press. 2000;9:206-213.
31. Licata G, Volpe M, Scaglione R, Rubattu S. Salt-regulating hormones in young normotensive obese subjects. Effects of saline load. Hypertension. 1994;23(1 Suppl):I20-I24.
32. De'Oliveira JM, Price DA, Fisher ND, Allan DR, McKnight JA, Williams GH, Hollenberg NK. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney Int. 1997;52:771-777.
33. Price DA, De'Oliveira JM, Fisher ND, Williams GH, Hollenberg NK. The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type II diabetes mellitus. Am J Hypertens. 1999;12(4 Pt 1):348-355.
34. Clerico A, Giannoni A, Vittorini S, Passino C. Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. Am J Physiol Heart Circ Physiol. 2011;301:H12-H20.
35. Cargill RI, Coutie WJ, Lipworth BJ. The effects of angiotensin II on circulating levels of natriuretic peptides. Br J Clin Pharmacol. 1994;38:139-142.
36. Shenker Y, Bates ER, Egan BH, Hammoud J, Grekin RJ. Effect of vasopressors on atrial natriuretic factor and hemodynamic function in humans. Hypertension. 1988;12:20-25.
37. Uehlinger DE, Zaman T, Weidmann P, Shaw S, Gnädinger MP. Pressure dependence of atrial natriuretic peptide during norepinephrine infusion in humans. Hypertension. 1987;10:249-253.
38. Anderson EA, Sinkey CA, Lawton WJ, Mark AL. Elevated sympathetic nerve activity in borderline hypertensive humans. Evidence from direct intraneural recordings. Hypertension. 1989;14:177-183.
39. Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J. 2012;33:1058-1066.
40. Sil A, Barr G. Assessment of predictive ability of Epworth scoring in screening of patients with sleep apnoea. J Laryngol Otol. 2012;126:372-379.
41. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic- nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361:932-934.